Practice Parameter for the Assessment and Treatment of Psychiatric Disorders in Children and Adolescents With Intellectual Disability (Intellectual Developmental Disorder) - 24/03/20
American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI)⁎
Christopher Bellonci, MD, Munya Hayek, MD, Helene Keable, MD, Carol Rockhill, MD, PhD, MPH, Oscar G. Bukstein, MD, MPH : AACAP CQI Co-Chairs, Heather J. Walter, MD, MPH : AACAP CQI Co-ChairsAbstract |
Intellectual disability (intellectual developmental disorder) (ID/IDD) is both a psychiatric disorder and a risk factor for co-occurring psychiatric disorders in children and adolescents. DSM-5 introduced important changes in the conceptualization and diagnosis of ID/IDD, and current research studies clarify assessment and treatment of co-occurring psychiatric disorders in this population. Optimal assessment and treatment of psychiatric illness in children and adolescents with ID/IDD includes modifications in diagnostic and treatment techniques, appreciation of variations in the clinical presentation of psychiatric disorders, an understanding of the spectrum of etiologies of behavioral disturbance, and knowledge of psychosocial and medical interventions.
Le texte complet de cet article est disponible en PDF.Key words : practice parameter, intellectual disability, child psychiatry, assessment, treatment
Plan
| Drs. Siegel and McGuire are co-first authors of this work. |
|
| This Practice Parameter was developed by Matthew Siegel, MD, Kelly McGuire, MD, MPA, Jeremy Veenstra-VanderWeele, MD, Katherine Stratigos, MD, Bryan King, MD, and the American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI) members: Christopher Bellonci, MD, Munya Hayek, MD, Helene Keable, MD, Carol Rockhill, MD, PhD, MPH and AACAP CQI Co-Chairs Oscar G. Bukstein, MD, MPH, and Heather J. Walter, MD, MPH. |
|
| AACAP Practice Parameters are developed by topic experts under the direction of the AACAP CQI with review by representatives from multiple constituent groups, including additional topic experts, AACAP members, relevant AACAP committees, the AACAP Assembly of Regional Organizations, and the AACAP Council. Final approval of a Practice Parameter as an AACAP Official Action is conferred by the AACAP Council. |
|
| The primary intended audience for the AACAP Practice Parameters is child and adolescent psychiatrists; however, the information presented also could be useful for other medical or behavioral health clinicians. |
|
| The authors acknowledge the following topic experts for their contributions to this Parameter: James Harris, MD, Ludwig Syzmanski, MD, and Roma Vasa, MD. |
|
| Jennifer Medicus, Stephanie Demian, and Karen Ferguson served as the AACAP staff liaisons for the CQI. |
|
| This Practice Parameter was reviewed by AACAP members in January and February 2018. |
|
| From April 2019 to May 2019, this Parameter was reviewed by a Consensus Group convened by the CQI. Consensus Group members and their constituent groups were Heather Walter, MD, Christopher Bellonci, MD, and Munya Hayek, MD (CQI); Ludwig Syzmanski, MD and Roma Vasa, MD (topic experts); AACAP Autism and Intellectual Disability Committee; Bettina Bernstein, MD, Jana Dreyzehner, MD, Michael Enenbach, MD, Michael Klaehn, MD, and Susan Rich, MD (AACAP Assembly of Regional Organizations); and Lisa Cullins, MD and Mary Ahn, MD (AACAP Council). |
|
| This Practice Parameter was approved by the AACAP Council on August 5, 2019. |
|
| This Practice Parameter is available at www.aacap.org/. |
|
| Disclosure: During the preparation of this Parameter, Drs. King, Siegel, and Stratigos had no financial conflicts of interest to disclose. Dr. McGuire received research support from Roche and the National Institute of Neurological Disorders and Stroke and served as consultant to Autism Speaks. Dr. Veenstra-VanderWeele received research support from the National Institutes of Health, the Health Resources and Services Administration, the Simons Foundation, Roche, Novartis, SynapDx, Seaside Therapeutics, Forest, and the Mortimer D. Sackler, MD, Family Foundation. Dr. Veenstra-VanderWeele served on advisory boards for Autism Speaks, the Brain and Behavior Research Foundation, Novartis, SynapDx, and Roche, and served on the editorial boards of JAMA Psychiatry, Autism Research, the Journal of Autism and Developmental Disorders, Autism, and Frontiers in Psychiatry: Child and Adolescent Psychiatry. Dr. Veenstra-VanderWeele received travel expenses from Autism Speaks and the Brain and Behavior Research Foundation and editorial stipends from Springer and Wiley. Dr. Bukstein received royalties from Routledge Press. Dr. Walter had no financial conflicts of interest to disclose. |
Vol 59 - N° 4
P. 468-496 - avril 2020 Retour au numéro
Article précédent
- Drs. Constantinou and Fonagy Reply:
- Matthew P. Constantinou, Peter Fonagy
- From Research to Practice: The Importance of Appropriate Outcome Selection, Measurement, and Reporting in Pediatric Mental Health Research
- Suneeta Monga, Martin Offringa, Nancy J. Butcher, Peter Szatmari
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?